WO2003057255A1 - Drugs against obeisty and drugs against fatty liver - Google Patents

Drugs against obeisty and drugs against fatty liver Download PDF

Info

Publication number
WO2003057255A1
WO2003057255A1 PCT/JP2002/013669 JP0213669W WO03057255A1 WO 2003057255 A1 WO2003057255 A1 WO 2003057255A1 JP 0213669 W JP0213669 W JP 0213669W WO 03057255 A1 WO03057255 A1 WO 03057255A1
Authority
WO
WIPO (PCT)
Prior art keywords
drugs against
fatty liver
obeisty
drugs
efficacious
Prior art date
Application number
PCT/JP2002/013669
Other languages
French (fr)
Japanese (ja)
Inventor
Katsumi Maezono
Nozomu Ishida
Koji Ohsumi
Nobuo Kondo
Original Assignee
Ajinomoto Co.,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co.,Inc. filed Critical Ajinomoto Co.,Inc.
Priority to AU2002367431A priority Critical patent/AU2002367431A1/en
Publication of WO2003057255A1 publication Critical patent/WO2003057255A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compounds having an effect of inhibiting acetyl CoA carboxylase, in particular, the following acylsulfonamide derivatives having a specific structure, analogs thereof and pharmaceutically acceptable salts thereof are efficacious as drugs against obesity or drugs against fatty liver.
PCT/JP2002/013669 2001-12-28 2002-12-26 Drugs against obeisty and drugs against fatty liver WO2003057255A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002367431A AU2002367431A1 (en) 2001-12-28 2002-12-26 Drugs against obeisty and drugs against fatty liver

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001401413A JP2005194191A (en) 2001-12-28 2001-12-28 Drug against obesity and therapeutic drug for fatty liver
JP2001-401413 2001-12-28

Publications (1)

Publication Number Publication Date
WO2003057255A1 true WO2003057255A1 (en) 2003-07-17

Family

ID=19189772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/013669 WO2003057255A1 (en) 2001-12-28 2002-12-26 Drugs against obeisty and drugs against fatty liver

Country Status (3)

Country Link
JP (1) JP2005194191A (en)
AU (1) AU2002367431A1 (en)
WO (1) WO2003057255A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2015036892A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5535931B2 (en) * 2008-10-27 2014-07-02 武田薬品工業株式会社 Bicyclic compound
WO2012108478A1 (en) * 2011-02-09 2012-08-16 武田薬品工業株式会社 Monocyclic compound
CN116059196A (en) * 2013-03-15 2023-05-05 斯克利普斯研究所 Compounds and methods for inducing cartilage formation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59164716A (en) * 1983-03-09 1984-09-17 Mitsubishi Chem Ind Ltd Biosynthetic inhibitor for fatty acid
JPH11171856A (en) * 1997-09-26 1999-06-29 Fujirebio Inc Acylsulfonamide derivative
WO2002002517A1 (en) * 2000-07-05 2002-01-10 Ajinomoto Co.,Inc. Acylsulfonamide derivatives
WO2002002101A1 (en) * 2000-07-05 2002-01-10 Ajinomoto Co., Inc. Hypoglycemics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59164716A (en) * 1983-03-09 1984-09-17 Mitsubishi Chem Ind Ltd Biosynthetic inhibitor for fatty acid
JPH11171856A (en) * 1997-09-26 1999-06-29 Fujirebio Inc Acylsulfonamide derivative
WO2002002517A1 (en) * 2000-07-05 2002-01-10 Ajinomoto Co.,Inc. Acylsulfonamide derivatives
WO2002002101A1 (en) * 2000-07-05 2002-01-10 Ajinomoto Co., Inc. Hypoglycemics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCCARTY M.F. ET AL.: "Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine", MEDICAL HYPOTHESES, vol. 56, no. 3, March 2001 (2001-03-01), pages 314 - 317, XP002965290 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2015036892A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris

Also Published As

Publication number Publication date
AU2002367431A1 (en) 2003-07-24
JP2005194191A (en) 2005-07-21

Similar Documents

Publication Publication Date Title
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
LU92496I2 (en) Combination of dapagliflozin or a pharmaceutically acceptable salt thereof and merformin or a pharmaceutically acceptable salt thereof as protected by EP1506211 B1
IL175953A (en) 3-cycloalkylaminopyrrolidine derivatives, pharmaceutically acceptable salts thereof and compositions comprising the same
NL300385I1 (en) Synergistic combinations including a renin inhibitor for cardiovascular diseases.
AU2003255845A1 (en) Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
AU2009201465A1 (en) Pharmaceutical Compositions with Improved Dissolution
WO2004013153A3 (en) Macrolide compounds endowed with antiinflammatory activity
IL157731A0 (en) Caboxylic acid derivatives and pharmaceutical compositions containing the same
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
WO2005117895A8 (en) Compositions comprising meloxicam
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
WO1999055332A8 (en) Medicinal compositions
AU2002354054A1 (en) Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
AU2002328494A1 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
AU2003245504A1 (en) Pharmaceutical compositions for drugs having ph-dependentsolubility
AU2002211208A1 (en) Solution-phase combinatiorial library synthesis and pharmaceutically active compounds produced thereby
EP1602645A4 (en) Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
EP1509220A4 (en) A pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4- 2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl -1-oxaspiro 2,5 octan-6-one
WO2003057255A1 (en) Drugs against obeisty and drugs against fatty liver
AU2001228810A1 (en) Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
AU4317500A (en) Antibiral compositions containing phorbol derivatives as the main active ingredient
WO2001007039A3 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP